Tumor fistulization associated with targeted therapy: Computed tomographic findings and clinical consequences

Journal of Computer Assisted Tomography

Volumn 35, Issue 1, 2011, Pages 86-90

  Chow, Henry ^a   Jung, Adam ^a   Talbott, Jason ^a   Lin, Amy M ^a   Daud, Adil I ^a   Coakley, Fergus V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis inhibitor; bevacizumab; fistula; sunitinib; VEGF inhibitor

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; HEALTH INSURANCE; PATIENT TREATMENT;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; C-MET INHIBITORS; COMPUTED TOMOGRAPHIC; FISTULA; GASTROINTESTINAL TRACT; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT COMPLIANT; MEAN AGES; SUNITINIB; VEGF INHIBITOR;

TUMORS;

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IMATINIB; IOHEXOL; IRINOTECAN; SUNITINIB; XL 184;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CLINICAL ASSESSMENT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PELVIS TUMOR; PERITONEUM METASTASIS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SPLEEN TUMOR; TRACHEOBRONCHIAL TREE; TUMOR DIAGNOSIS; TUMOR FISTULARIZATION; TUMOR FISTULIZATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VISCERAL METASTASIS;

EID: 79551565252     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3181fce2cb     Document Type: Article

References (11)

1. Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol. 2010;16:2726-2734.
2. Van den Abbeele AD, for the GIST Collaborative PET Study Group, Dana-Farber Cancer Institute, Boston, Massachusetts; OHSU, Portland, Oregon; Helsinki University Central Hospital, Turku University Central Hospital, Finland; Novartis Oncology. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001;20:362a.
3. Asmis TR, Chung KY, Teitcher JB, et al. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs. 2008;26:95-96.
4. Kou CJ. Overview of angiogenesis inhibitors. In: UpToDate. Goldberg RM, ed. Waltham, MA: UpToDate; 2010.
5. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer. Gynecol Oncol. 2007;105:3-6.
6. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
7. Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
8. Exelixis Inc. Study of XL184 in Adults With Advanced Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2010 June 13]. Available at: http://clinicaltrials.gov/ct2/show/ NCT00215605 NLM Identifier: NCT00215605. Accessed June 13, 2010.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Cassidy J, Saltz LB, Giantonio BJ. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136:737-743.
11. Faivre S, Delbaldo C, Vera K. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.